Vendor Intelligence Report: Peptide Crafters

Published 29 Jul 2026. 27-page investigative report on who is behind Peptide Crafters: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 41 Finnrick lab tests, Peptide Crafters records 27 pass / 14 fail — an overall pass rate of 66%. The signal is uneven, not uniformly bad: Semaglutide is the clear bright spot, CJC-1295 is the weakest tested line, and Melanotan II plus BPC-157 expose the fill and dosing-consistency problem. Ratings contract under stricter methodology, so dose precision matters more than a purity-only glance suggests.

The non-lab record is compressed. The domain starts in early 2024 as a generic web-agency template, pivots to a peptide storefront within months, then ties into a USPTO trademark trail that later becomes dead/abandoned. Reviewed policies did not disclose a responsible legal entity, and registry checks produced negative or unresolved results rather than a clean corporate anchor.

The buying surface adds friction: a login-gated storefront, archived payment language limited to Venmo, Zelle, and bank-transfer rails, and no open proof of pharmacy, outsourcing-facility, domestic-manufacturing, or supplier-origin status. Certificate-transparency records and public promotions show partner, funnel, and tracking infrastructure with referral-style posts across X, Reddit, review pages, and coupon sites.

This is not a blanket safe/unsafe call. For buyers determined to use Peptide Crafters, Semaglutide is the comparatively defensible tested line; the weaker peptides need a current independent lot test or a better-testing vendor. The full report separates those choices instead of letting one good product launder the catalog.

Inside the full report:

  • Appendix A Finnrick pass/fail data and methodology-divergence charts for all seven products
  • Wayback timeline from web-agency template to peptide storefront and login gate
  • USPTO serial 99428140 trail, abandonment status, and corporate-registry checks
  • Archived claims review covering non-503A/non-503B status and supplier disclosures
  • Payment, Trustpilot, support, and buyer-recourse analysis
  • Affiliate scan across subdomains, X, Reddit, review pages, and coupon aggregators

Risk assessment

  • CJC-1295 quality risk — high: CJC-1295 is 4 tests, 0 pass / 4 fail with a 21.39% Finnrick rating; test-detail records include CJC-1295 DAC purity failures.
  • BPC-157 and Melanotan II dose-accuracy risk — high: BPC-157 is 6 tests, 3 pass / 3 fail with a 50.54% rating; Melanotan II is 4 tests, 2 pass / 2 fail with a 57.62% rating and repeated severe underfills in test-detail captures.
  • Corporate-transparency and legal-recourse risk — high: No legal entity is disclosed in reviewed site policies; USPTO mark is abandoned/dead, current TSDR shows individual-owner trail and Sheridan WY owner location; Delaware/OpenCorporates searches found no entity and Texas SOS remains unresolved.
  • Irreversible-payment buyer-protection risk — high: Captured payment policy listed Venmo, Zelle, and ACH/Pay by Bank with no credit-card option; current public experience is gated, leaving chargeback options unproven.
  • Undisclosed affiliate-promotion risk — medium: Affiliate scan found referral codes/links across X, Reddit, and coupon/review pages; clear material-connection disclosure was absent for most referral-carrying promotion.
  • Customer-support and fulfillment reliability risk — medium: Trustpilot aggregate is positive, but the unclaimed profile includes recent one-star complaints about delayed responses and unresolved order issues.